KBC Group’s Harmony Biosciences HRMY Stock Holding History

KBC Group’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67K	Hold	1,844	–	–	﹤0.01%	1608
2026 Q1	$52K	Hold	1,844	–	–	﹤0.01%	1633
2025 Q4	$69K	Hold	1,844	–	–	﹤0.01%	1505
2025 Q3	$51K	Hold	1,844	–	–	﹤0.01%	1641
2025 Q2	$58K	Hold	1,844	–	–	﹤0.01%	1534
2025 Q1	$61K	Hold	1,844	–	–	﹤0.01%	1727
2024 Q4	$63K	Buy	1,844 +819	+80%	+$28.1K	﹤0.01%	1768
2024 Q3	$41K	Hold	1,025	–	–	﹤0.01%	1776
2024 Q2	$31K	Hold	1,025	–	–	﹤0.01%	1811
2024 Q1	$34K	Hold	1,025	–	–	﹤0.01%	1728
2023 Q4	$33K	Sell	1,025 -248	-19%	-$6.92K	﹤0.01%	1765
2023 Q3	$42K	Sell	1,273 -1,188	-48%	-$41.2K	﹤0.01%	1585
2023 Q2	$87K	Hold	2,461	–	–	﹤0.01%	1234
2023 Q1	$80K	Hold	2,461	–	–	﹤0.01%	1273
2022 Q4	$136K	Hold	2,461	–	–	﹤0.01%	1089
2022 Q3	$109K	Buy	2,461 +458	+23%	+$22.3K	﹤0.01%	1154
2022 Q2	$98K	Buy	+2,003	New	+$90.2K	﹤0.01%	1227

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's HRMY Position: Q2 2026 in Review

KBC Group held its Harmony Biosciences (HRMY) position steady in Q2 2026 at 1,844 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #1608.

KBC Group first reported a position in HRMY in Q2 2022 and has held it in 17 quarters since. The position peaked at $136K in Q4 2022. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

KBC Group held 1,844 shares of Harmony Biosciences worth $67K as of Q2 2026.
KBC Group left its Harmony Biosciences share count unchanged in Q2 2026.
Harmony Biosciences made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1608 holding.
KBC Group first reported a position in Harmony Biosciences in Q2 2022 and has held it in 17 quarters since.
KBC Group's Harmony Biosciences position peaked at $136K in Q4 2022.
327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.